Optimizing diagnostic testing for venous thromboembolism

Patrick Rendon; Taylor Goot; Allison E. Burnett; Michael B. Streiff; Jessica Zimmerberg-Helms

doi:10.3949/ccjm.84a.16049

ABSTRACT

Diagnostic algorithms for venous thromboembolism exist, but most do not provide detailed guidance as to which patients, if any, may benefit from screening for thrombophilia. This article provides an overview of the optimized diagnosis of venous thromboembolism, with a focus on the appropriate use of thrombophilia screening.

Footnotes

Dr. Streiff has disclosed that he is an independent contractor or consultant for Boehringer Ingelheim, Janssen Research & Development, Portola Pharmaceuticals, and Roche Diagnostics.

View Full Text

Patrick Rendon, MD⇑

Assistant Professor, Department of Internal Medicine, University of New Mexico Hospital, Albuquerque, NM

ADDRESS:
Patrick Rendon, MD, Department of Internal Medicine, University of New Mexico Hospital, MSC 10 5550 - 1 University of New Mexico, Albuquerque, NM 87131-0001; prendon{at}salud.unm.edu

Taylor Goot, MD

Assistant Professor, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM

Allison E. Burnett, PharmD, PhC, CACP

Clinical Assistant Professor, University of New Mexico College of Pharmacy, Inpatient Antithrombosis Service, University of New Mexico Hospital, Albuquerque, NM

Michael B. Streiff, MD

Associate Professor, Department of Medicine, Division of Hematology, Johns Hopkins School of Medicine, Baltimore, MD

Jessica Zimmerberg-Helms, MD

Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM

ABSTRACT

Footnotes

Dr. Streiff has disclosed that he is an independent contractor or consultant for Boehringer Ingelheim, Janssen Research & Development, Portola Pharmaceuticals, and Roche Diagnostics.

View Full Text